Related Experiment Video

Updated: Jun 2, 2026

Reprogramming Pancreatic Ductal Adenocarcinoma to Pluripotency
07:08

Reprogramming Pancreatic Ductal Adenocarcinoma to Pluripotency

Published on: February 2, 2024

Nrf2 is overexpressed in pancreatic cancer: implications for cell proliferation and therapy

Adam Lister1, Taoufik Nedjadi, Neil R Kitteringham

  • 1MRC Centre for Drug Safety Science, Department of Molecular and Clinical Pharmacology, Institute of Translational Medicine, University of Liverpool, UK.

Molecular Cancer
|April 15, 2011
PubMed
Abstract

Insights

The Nrf2/Keap1 system, crucial for cellular defense, is upregulated in pancreatic cancer. Inhibiting Nrf2 may reduce tumor growth and enhance chemotherapy effectiveness.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • The Nuclear factor erythroid 2-related factor 2 (Nrf2) pathway regulates genes involved in drug metabolism and oxidative stress defense.
  • Kelch-like ECH-associated protein 1 (Keap1) typically targets Nrf2 for degradation, controlling its activity.
  • Dysregulation of the Nrf2/Keap1 system is implicated in various cancers, influencing proliferation and treatment response.

Purpose of the Study:

  • To investigate the integrity and role of the Nrf2/Keap1 system in pancreatic cancer.
  • To determine if Nrf2/Keap1 alterations contribute to pancreatic tumor development or progression.

Main Methods:

  • Analysis of Nrf2 and Keap1 expression and mutations in pancreatic cancer cell lines and patient tumors.
  • RNA interference (RNAi) to deplete Nrf2 and assess its impact on cell proliferation and drug sensitivity.
  • Immunohistochemical analysis of Nrf2 and Keap1 in tumor tissues versus normal epithelium.

Main Results:

  • Nrf2 and Keap1 were detected in pancreatic cancer cell lines, with no significant mutations found in NRF2 or KEAP1.
  • Nrf2 depletion reduced proliferation and increased sensitivity to gemcitabine, 5-fluorouracil, cisplatin, and radiation in pancreatic cancer cells.
  • Nrf2 cytoplasmic expression was significantly elevated in pancreatic ductal adenocarcinomas compared to normal tissue.

Conclusions:

  • Nrf2 expression is upregulated in pancreatic cancer, suggesting enhanced cellular defense and resistance mechanisms.
  • Nrf2 supports proliferation in some pancreatic adenocarcinomas.
  • Targeting Nrf2 pharmacologically could be a therapeutic strategy to inhibit pancreatic tumor growth and improve treatment outcomes.

More Related Videos

Multianimal Magnetic Resonance Imaging for Tumor Measurements in Pancreatic Cancer Mouse Models09:18

Multianimal Magnetic Resonance Imaging for Tumor Measurements in Pancreatic Cancer Mouse Models

Published on: February 3, 2026

Ultrasound-Guided Orthotopic Implantation of Murine Pancreatic Ductal Adenocarcinoma06:21

Ultrasound-Guided Orthotopic Implantation of Murine Pancreatic Ductal Adenocarcinoma

Published on: November 19, 2019

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
NF-κB-dependent Signaling Pathway02:26

NF-κB-dependent Signaling Pathway

The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The heterodimer of NF-κB...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...